Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?

Simply Wall St.07-10 00:32

AdvertisementWhat Corcept’s Index Removal Could Mean for Investors Corcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650976961?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-10 00:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650976961","market":"us","top_or_hot":-1,"title":"Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat Corcept’s Index Removal Could Mean for Investors Corcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 00:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat Corcept’s Index Removal Could Mean for Investors Corcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","article_id":"2650976961","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650976961","pubTimestamp":1783614761,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What Corcept’s Index Removal Could Mean for Investors\nCorcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a shift that can influence trading activity as index funds rebalance positions.\nFor you as an investor, these index changes are less about Corcept Therapeutics business operations and more about how institutional owners that track these benchmarks may adjust their holdings. Such rebalancing can affect short...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股","PSCH":"Invesco S&P SmallCap Health Care ETF","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","BK4532":"文艺复兴科技持仓","FBT":"First Trust NYSE Arca Biotechnology Index Fund"},"translate_title":"Corcept Therapeutics (CORT) 的 Russell 指数移除是否得到了充分估值？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBT":0.6,"PSCH":0.6,"CORT":1.5},"content_text":"AdvertisementWhat Corcept’s Index Removal Could Mean for Investors Corcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a shift that can influence trading activity as index funds rebalance positions. For you as an investor, these index changes are less about Corcept Therapeutics business operations and more about how institutional owners that track these benchmarks may adjust their holdings. Such rebalancing can affect short term liquidity, trading volumes, and price volatility without necessarily signaling a change in the company’s underlying fundamentals. This can be a useful moment to step back and compare the stock’s recent performance and financial profile with what index linked selling or buying pressure might be doing to the share price in the near term. See our latest analysis for Corcept Therapeutics. Over the past year, Corcept Therapeutics has combined strong upward share price momentum, including a 26.7% 1 month share price return and a 120% 3 month share price return, with a 31.1% 1 year total shareholder return and a very large 5 year total shareholder return. As a result, the recent index removal may be intersecting with a period where sentiment and expectations are already elevated. If this type of move has you looking beyond a single stock, it could be a good moment to see what else is setting the pace in healthcare by checking out 40 healthcare AI stocks. After such a sharp run, and with Corcept Therapeutics trading slightly above its recent analyst price target and intrinsic value estimate, does the current balance of risk and reward still lean in favour of new buyers, or is enthusiasm already priced in? Most Popular Narrative: 6% Overvalued Corcept Therapeutics last closed at $92.94, slightly above the most followed fair value estimate of $88, which is built using a 7.1% discount rate and detailed long term forecasts.  The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years.  Read the complete narrative. Read the complete narrative. Curious what kind of revenue curve, margin profile and earnings power that fair value leans on? The narrative is based on aggressive compounding and a leaner cost base. The exact assumptions may surprise you. Result: Fair Value of $88 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Corcept Therapeutics still faces meaningful uncertainty, including Korlym patent litigation and the possibility that relacorilant approvals or uptake differ from analysts’ expectations. Find out about the key risks to this Corcept Therapeutics narrative. Next Steps If this mix of optimism and concern around Corcept Therapeutics feels familiar, take a moment now to review the details and weigh the trade off using the 1 key reward and 1 important warning sign. Looking for more Corcept Therapeutics sized opportunities? If Corcept Therapeutics has you thinking bigger about your portfolio, now is a strong time to widen your watchlist with a few focused stock ideas.  Spot underappreciated quality by scanning companies that pair healthy fundamentals with attractive pricing using the 44 high quality undervalued stocks. Strengthen your downside protection by zeroing in on businesses with sturdy finances through the solid balance sheet and fundamentals stocks screener (47 results). Get ahead of the crowd by reviewing the screener containing 19 high quality undiscovered gems before these opportunities gain wider attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650976961","isCrawlerRequest":true}